270 related articles for article (PubMed ID: 23845840)
1. Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy.
Price JG; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):842-7. PubMed ID: 23845840
[TBL] [Abstract][Full Text] [Related]
2. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer.
Lesperance RN; Kjorstadt RJ; Halligan JB; Steele SR
Am J Surg; 2008 May; 195(5):616-20; discussion 620. PubMed ID: 18374892
[TBL] [Abstract][Full Text] [Related]
3. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
[TBL] [Abstract][Full Text] [Related]
4. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
Akimoto T; Katoh H; Kitamoto Y; Tamaki T; Harada K; Shirai K; Nakano T
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):364-70. PubMed ID: 16690428
[TBL] [Abstract][Full Text] [Related]
5. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579
[TBL] [Abstract][Full Text] [Related]
6. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
[TBL] [Abstract][Full Text] [Related]
8. Novel parameter predicting grade 2 rectal bleeding after iodine-125 prostate brachytherapy combined with external beam radiation therapy.
Shiraishi Y; Hanada T; Ohashi T; Yorozu A; Toya K; Saito S; Shigematsu N
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):182-7. PubMed ID: 23747214
[TBL] [Abstract][Full Text] [Related]
9. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.
Kishan AU; Kupelian PA
Brachytherapy; 2015; 14(2):148-59. PubMed ID: 25516492
[TBL] [Abstract][Full Text] [Related]
12. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
13. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.
Cesaretti JA; Stock RG; Atencio DP; Peters SA; Peters CA; Burri RJ; Stone NN; Rosenstein BS
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1410-6. PubMed ID: 17490827
[TBL] [Abstract][Full Text] [Related]
14. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
15. Incidence and clinical course of hemorrhagic radiation proctitis after iodine-125 prostate brachytherapy.
Mishra MV; Shirazi R; Barrett WL
Clin Genitourin Cancer; 2007 Sep; 5(6):397-400. PubMed ID: 17956713
[TBL] [Abstract][Full Text] [Related]
16. Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management.
Phan J; Swanson DA; Levy LB; Kudchadker RJ; Bruno TL; Frank SJ
Cancer; 2009 May; 115(9):1827-39. PubMed ID: 19248043
[TBL] [Abstract][Full Text] [Related]
17. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M
Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159
[TBL] [Abstract][Full Text] [Related]
18. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors.
Shah JN; Ennis RD
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):817-24. PubMed ID: 16297567
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
20. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
